



ASX ANNOUNCEMENT

26 October 2015

Resignation of Non-Executive Director

Brisbane, 26th October 2015: The Board of Tissue Therapies (ASX:TIS) announces the resignation of Non-Executive Director, Dr Mel Bridges, which will take effect following the Company's Annual General Meeting on Wednesday, 25 November 2015.

Dr Bridges has served on the Tissue Therapies Board since 2009, helping guide the company through a number of important milestones and challenges.

"I fully endorse the strategic direction for Tissue Therapies going forward, and support the current regulatory initiative. Our lead therapeutic has significant potential and deserves to come to market," Dr Bridges said.

Tissue Therapies Chairman, Dr Cherrell Hirst, said: "On behalf of the Board of Directors I acknowledge Dr Bridges' contribution to Tissue Therapies and sincerely thank him for his service to the Company."

- ENDS -

For more information

Dr Cherrell Hirst, Chairman Tissue Therapies Limited Cherrell@hirst.com	Kyahn Williamson Buchan Consulting Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au
---	--

About Tissue Therapies Limited

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. Tissue Therapies Limited is commercialising VitroGro® ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company owns various patent families related to wound healing and other therapeutic uses. Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges. For more information, please visit www.tissuetherapies.com.